Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course radiotherapy followed by cadonilimab plus CapeOX before TME in locally advanced rectal cancer
ChiCTR2300067545Phase 2Not yet recruiting
- Sponsor
- Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
- Start
- Oct 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in rectal adenocarcinoma, sponsored by Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. Primary endpoint: Pathological complete response rate. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300067545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067545.